Generics in Japan

August 2020 | 45 pages | ID: GDBE6BEE215EN
MarketLine

Abstracts

Generics in Japan

SUMMARY

Generics in Japan industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2015-19, and forecast to 2024). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

KEY HIGHLIGHTS

• For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
• The Japanese generics market had total revenues of $27.4bn in 2019, representing a compound annual growth rate (CAGR) of 4.1% between 2015 and 2019.
• Market consumption volume increased with a CAGR of 7.1% between 2015 and 2019, to reach a total of 78.4% in 2019.
• Growth of the generic market share in Japan has been strong, but it is expected to be slower in the forecast period as readiness regarding the adoption of generics slows, and the market becomes closer to full saturation.

SCOPE

• Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in Japan
• Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Japan
• Leading company profiles reveal details of key generics market players’ global operations and financial performance
• Add weight to presentations and pitches by understanding the future growth prospects of the Japan generics market with five year forecasts by both value and volume

REASONS TO BUY

• What was the size of the Japan generics market by value in 2019?
• What will be the size of the Japan generics market in 2024?
• What factors are affecting the strength of competition in the Japan generics market?
• How has the market performed over the last five years?
• How large is Japan’s generics market in relation to its regional counterparts?

Contents

1 EXECUTIVE SUMMARY

1.1. Market value
1.2. Market value forecast
1.3. Market volume
1.4. Market volume forecast
1.5. Geography segmentation
1.6. Market rivalry
1.7. Competitive Landscape

2 MARKET OVERVIEW

2.1. Market definition
2.2. Market analysis

3 MARKET DATA

3.1. Market value
3.2. Market volume

4 MARKET SEGMENTATION

4.1. Geography segmentation

5 MARKET OUTLOOK

5.1. Market value forecast
5.2. Market volume forecast

6 FIVE FORCES ANALYSIS

6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry

7 COMPETITIVE LANDSCAPE

7.1. Who are the leading players?
7.2. What are the strengths of the leading players?
7.3. Has there been any significant recent M&A activity?
7.4. How has the outbreak of COVID-19 impacted leading players?

8 COMPANY PROFILES

8.1. Teva Pharmaceutical Industries Limited
8.2. Daiichi Sankyo Co Ltd
8.3. Sawai Pharmaceutical Co Ltd
8.4. Lupin Ltd

9 MACROECONOMIC INDICATORS

9.1. Country data

10 APPENDIX

10.1. Methodology
10.2. Industry associations
10.3. Related MarketLine research
10.4. About MarketLine

List Of Tables

LIST OF TABLES

Table 1: Japan generics market value: $ billion, 2015-19
Table 2: Japan generics market volume: % of total pharma, 2015-19
Table 3: Japan generics market geography segmentation: $ billion, 2019
Table 4: Japan generics market value forecast: $ billion, 2019-24
Table 5: Japan generics market volume forecast: % of total pharma, 2019-24
Table 6: Teva Pharmaceutical Industries Limited: key facts
Table 7: Teva Pharmaceutical Industries Limited: Annual Financial Ratios
Table 8: Teva Pharmaceutical Industries Limited: Key Employees
Table 9: Daiichi Sankyo Co Ltd: key facts
Table 10: Daiichi Sankyo Co Ltd: Annual Financial Ratios
Table 11: Daiichi Sankyo Co Ltd: Key Employees
Table 12: Daiichi Sankyo Co Ltd: Key Employees Continued
Table 13: Daiichi Sankyo Co Ltd: Key Employees Continued
Table 14: Daiichi Sankyo Co Ltd: Key Employees Continued
Table 15: Sawai Pharmaceutical Co Ltd: key facts
Table 16: Sawai Pharmaceutical Co Ltd: Annual Financial Ratios
Table 17: Sawai Pharmaceutical Co Ltd: Key Employees
Table 18: Lupin Ltd: key facts
Table 19: Lupin Ltd: Annual Financial Ratios
Table 20: Lupin Ltd: Key Employees
Table 21: Lupin Ltd: Key Employees Continued
Table 22: Japan size of population (million), 2015-19
Table 23: Japan gdp (constant 2005 prices, $ billion), 2015-19
Table 24: Japan gdp (current prices, $ billion), 2015-19
Table 25: Japan inflation, 2015-19
Table 26: Japan consumer price index (absolute), 2015-19
Table 27: Japan exchange rate, 2015-19

List Of Figures

LIST OF FIGURES

Figure 1: Japan generics market value: $ billion, 2015-19
Figure 2: Japan generics market volume: % of total pharma, 2015-19
Figure 3: Japan generics market geography segmentation: % share, by value, 2019
Figure 4: Japan generics market value forecast: $ billion, 2019-24
Figure 5: Japan generics market volume forecast: % of total pharma, 2019-24
Figure 6: Forces driving competition in the generics market in Japan, 2019
Figure 7: Drivers of buyer power in the generics market in Japan, 2019
Figure 8: Drivers of supplier power in the generics market in Japan, 2019
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Japan, 2019
Figure 10: Factors influencing the threat of substitutes in the generics market in Japan, 2019
Figure 11: Drivers of degree of rivalry in the generics market in Japan, 2019